Elicera Therapeutics
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024
Margareth Jorvid, board member of Elicera Therapeutics, will participate in a networking session to present the company's scientific abstract entitled "The iTANK platform has potential to improve CAR-T cell treatment of solid tumors".
ISCT brings together leading researchers, clinicians and industry experts in cell and gene therapy from around the world. The main purpose of the conference is to promote the exchange of new scientific advances, technological advances and clinical insights in the rapidly developing field of cell and gene therapy. For more information: www.isctglobal.org/isct2024.
Datum | 2024-02-16, kl 10:14 |
Källa | Cision |